Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Irbesartan; Ramipril